Panelists at the DIA Biosimilars Conference discussed how biosimilars can help address health care disparities and why patient notification for switching to biosimilars must be handled with caution.
Patients who are about to be switched from a reference product to a biosimilar need to receive adequate and transparent notification prior to the switch to ensure biosimilar adoption and that biosimilars, panelists argued.
The panelists, who presented at the DIA Biosimilars Conference in Arlington, Virginia from September 20, 2022 to September 21, 2022; outlined how better patient notification and education can encourage biosimilar uptake and address health disparities by providing patients better savings and access to treatments.
Murray Aitken, MBA, executive director of IQVIA Institute for Human Data Science, mentioned how the promise of biosimilars savings could help keep a health system running and serve as an avenue to address high drug prices and ensure medication adherence.
“At a very big level, we know that biosimilars have a critical role to play in bringing lower cost biologic therapies to more patients and thereby, contribute to the sustainability of the health system level, as well as advancing population health and individual patient outcomes by making those biologic therapeutics available to more people. I think, in that context, biosimilars also have an important role to play in addressing disparities that we see in individual patient outcomes or groups of patients,” said Aitken.
Aitken noted how the savings potential of biosimilars has grown from $25 billion in the last 5 years to $70 billion in the next 5 years, saying that the market share of newer biosimilar molecules is increasing to a higher level at a faster rate.
“At the end of the day, the longer-term success of biosimilars as a meaningful part of health systems does rely on multiple companies willing to make the investments and take the risks to bring forward the next generation of biosimilars,” Aitken concluded.
Terry Wilcox, co-founder and CEO of Patients Rising, gave examples of 2 patients who had received notification of a coverage change in the mail. Although the first dealt with the switch and was fine, the second stressed out and missed their infusion date as they tried to figure out what had happened, leading to poorer clinical outcomes and higher medical bills as they tried to get back on their regimen.
“One of the biggest things that I think that we can do from a patient perspective and adopter perspective is figure out how we can show patients that savings and give doctors the tools to help show patients those savings," Wilcox said. "Right now, everything's very much in a black box and nothing's transparent about it. And so, if you want patients to go along [with biosimilars], then you have to show them what the benefits are for them. And a scary letter in the mail is not the answer."
Wilcox suggested that more physicians, pharmacists, and nurses need to have discussions with patients about biosimilars and the possibility that the product they are currently receiving could change. This is especially important as more interchangeable biosimilars enter the market, and patients and/or their providers may not be notified that a switch has been made depending on state laws in place.
Anna Hyde, MA, vice president of advocacy and access at the Arthritis Foundation, described the complexities of switching patients with chronic conditions who have been stable on the reference product for many years, which could become even more contentious as up to 10 biosimilars referencing Humira (adalimumab) are expected to enter the market and shake up coverage options in 2023.
“There's an emotional component there that I cannot overemphasize. So, even if you tell a patient that something is clinically the same, or whatever words that you want to use to make a patient understand, they're essentially taking the same medication. If the patient knows that it's technically something different, they don't want to ‘rock the boat’,” Hyde explained.
Additionally, Hyde emphasized that every patient may be on their own journey with their condition and suddenly switching to a biosimilar because of a coverage change can be very stressful for patients who have had to try several medications before finding one that works for them.
Hyde concluded, “Meeting them where they fit and where they are doing with their respective disease is critical to getting [biosimilar] uptake from the bottom up.”
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in New Zealand in 2022.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.